A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
Study at a Glance
Estimated Time Commitment
To be discussedEligibility
Healthy adults ages 18 to 50
Diagnosis Required
NoneDiseases Being Studied
HIV PreventionClinical Trials.gov reference NCT05001373
First in-human trial for a HIV vaccine using the mRNA platform.
Meet Your Clinical Research Team
Contact us
Principal Investigator: Local PI: Barbara Taylor, MD, MSFor more information on this study, please contact Dr. Barbara Taylor at taylorb4@uthscsa.edu